Benztropine Mesylate

CHEMBL1200383 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
403.5 g/mol
LogP
Phase
4

The mesylate salt form of benztropine, an anticholinergic drug used to relieve Parkinson's symptoms and drug-induced movement disorders. It helps reduce tremor, muscle stiffness, and involuntary movements by blocking certain nerve signals. Common side effects include dry mouth, blurred vision, and constipation.

Berat Molekul

403,5000 g/mol

TPSA

75,20 Ų

Area Terapeutik

Mekanisme Kerja

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O

InChI

InChI=1S/C21H25NO.CH4O3S/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17;1-5(2,3)4/h2-11,18-21H,12-15H2,1H3;1H3,(H,2,3,4)/t18-,19+,20+;

Molecular Formula

C22H29NO4S

HBD / HBA

1 / 5

Ikatan yang Dapat Dirotasi

4

Atom Berat

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The mesylate salt form of benztropine, an anticholinergic drug used to relieve Parkinson's symptoms and drug-induced movement disorders. It helps reduce tremor, muscle stiffness, and involuntary movements by blocking certain nerve signals. Common side effects include dry mouth, blurred vision, and constipation.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Benztropine Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200383. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 238053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.